Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heparin-induced thrombocytopenia.

B H Chong1, M C Berndt

  • 1Haematology Department, St. George Hospital, Kogarah, New South Wales, Australia.

Blut
|February 1, 1989
PubMed
Summary

Heparin therapy can cause thrombocytopenia, a low platelet count. Type I is mild, while Type II heparin-induced thrombocytopenia is severe and requires immediate cessation of heparin.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical relevance of nitrated beta 2-glycoprotein I in antiphospholipid syndrome: Implications for thrombosis risk.

Journal of autoimmunity·2021
Same author

Quantification of NETs-associated markers by flow cytometry and serum assays in patients with thrombosis and sepsis.

International journal of laboratory hematology·2018
Same author

Activation of tumour cell ECM degradation by thrombin-activated platelet membranes: potentially a P-selectin and GPIIb/IIIa-dependent process.

Clinical & experimental metastasis·2015
Same author

Recommendations for the use of the non-obese diabetic/severe combined immunodeficiency mouse model in autoimmune and drug-induced thrombocytopenia: communication from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2015
Same author

Primary haemostasis: newer insights.

Haemophilia : the official journal of the World Federation of Hemophilia·2014
Same author

The role of Nox1 and Nox2 in GPVI-dependent platelet activation and thrombus formation.

Redox biology·2014

Area of Science:

  • Hematology
  • Pharmacology
  • Immunology

Background:

  • Thrombocytopenia is a common complication of heparin anticoagulant therapy.
  • Two distinct types of heparin-induced thrombocytopenia (HIT) exist with different mechanisms and clinical implications.

Purpose of the Study:

  • To differentiate between Type I and Type II heparin-induced thrombocytopenia.
  • To elucidate the distinct etiologies and management strategies for each type of HIT.

Main Methods:

  • Clinical observation and characterization of thrombocytopenia in patients receiving heparin.
  • Distinguishing between early-onset mild thrombocytopenia (Type I) and delayed-onset severe thrombocytopenia (Type II).

Main Results:

  • Type I HIT presents with mild thrombocytopenia early in therapy, often manageable without stopping heparin.
  • Type II HIT is characterized by severe thrombocytopenia occurring 7-10 days after heparin initiation, linked to heparin-dependent antibodies.
  • Type II HIT involves platelet aggregation mediated by heparin-antibody complexes binding to platelet Fc receptors.

Conclusions:

  • Immediate cessation of heparin is crucial for Type II HIT management.
  • Type I HIT requires monitoring but not necessarily discontinuation of heparin therapy.
  • Understanding the distinct mechanisms of Type I and Type II HIT is vital for appropriate patient management and preventing severe complications.

Related Experiment Videos